Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer
Irinotecan Combined With Infusional 5-FU/Folinic Acid or Capecitabine and the Role of Celecoxib in Patients With Metastatic Colorectal Cancer
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Listed as NCT00064181, this PHASE3 trial focuses on Colorectal Cancer and remains completed. Sponsored by European Organisation for Research and Treatment of Cancer - EORTC, it has been updated 6 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
May 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- European Organisation for Research and Treatment of Cancer - EORTC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Antwerp, Belgium , Berlin, Germany , Brussels, Belgium , Budapest, Hungary , Cairo, Egypt , Celle, Germany , Dresden, Germany , Edegem, Belgium , Essen, Germany , Frankfurt, Germany and 16 more locations